Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy

Journal of Thrombosis and Thrombolysis

Volumn 33, Issue 3, 2012, Pages 246-257

  Voora, Deepak ^a   Ortel, Thomas L ^a   Lucas, Joseph E ^a   Chi, Jen Tsan ^a   Becker, Richard C ^a   Ginsburg, Geoffrey S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aspirin; Light transmittance aggregometry; PFA100; Platelets; Principal components analysis

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; COLLAGEN; CYCLOOXYGENASE 1; INSULIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; THROMBOXANE B2; PTGS1 PROTEIN, HUMAN;

ADULT; ARACHIDONIC ACID AGGREGOMETRY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DYNAMICS; ENZYME ACTIVITY; ENZYME REPRESSION; FEMALE; HUMAN; IN VITRO STUDY; LIGHT TRANSMITTANCE AGGREGOMETRY; MAJOR CLINICAL STUDY; MALE; NON COX 1 DEPENDENT PLATELET FUNCTION; PILOT STUDY; PLATELET FUNCTION SCORE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; THROMBOCYTE FUNCTION; TIME; TREATMENT DURATION; TREATMENT RESPONSE; AGED; BLOOD CLOTTING PARAMETERS; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECT; METHODOLOGY; MIDDLE AGED; PHYSIOLOGY; THROMBOCYTE;

ADULT; AGED; ASPIRIN; BLOOD PLATELETS; COHORT STUDIES; CYCLOOXYGENASE 1; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PLATELET FUNCTION TESTS; TIME FACTORS; YOUNG ADULT;

EID: 84871704564     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0683-0     Document Type: Article

References (32)

1. Soni A (2007) Aspirin use among the adult U.S. noninstitutionalized population, with and without indicators of heart disease, 2005. http://meps.ahrq.gov/mepsweb/data-files/publications/st179/stat179.pdf. Accessed 11 Jan 2012
2. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD (2007) Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 50(19):1822-1834. doi: 10.1016/j.jacc.2007.07.051
3. Yee DL, Sun CW, Bergeron AL, Dong JF, Bray PF (2005) Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 106(8):2723-2729
4. FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ II, Lawson JA, Brash AR (1983) Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 71(3):676-688
5. Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi F (2004) Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 43(6):979-984
6. Perneby C, Wallen NH, Rooney C, Fitzgerald D, Hjemdahl P (2006) Dose-and time-dependent antiplatelet effects of aspirin. Thromb Haemost 95(4):652-658
7. Faraday N, Yanek LR, Mathias R, Herrera-Galeano JE, Vaidya D, Moy TF, Fallin MD, Wilson AF, Bray PF, Becker LC, Becker DM (2007) Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 115(19):2490-2496
8. Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US (2007) Evaluation of dose-related effects of aspirin on platelet function: Results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 115(25):3156-3164
9. Frelinger AL III, Li Y, LindenMD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD (2009) Association of cyclooxygenase-1-dependent and-independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 120(25):2586-2596. doi: 10.1161/circulationaha.109.900589
10. Born GV (1964) Strong inhibition by 2-chloroadenosine of the aggregation of blood platelets by adenosine diphosphate. Nature 202:95-96
11. Mori TA, Vandongen R, Douglas AJ, McCulloch RK, Burke V (1992) Differential effect of aspirin on platelet aggregation in IDDM. Diabetes 41(3):261-266
12. Schwartz KA, Schwartz DE, Pittsley RA, Mantz SL, Ens G, Sami A, Davis JM (2002) A new method for measuring inhibition of platelet function by nonsteroidal antiinflammatory drugs. J Lab Clin Med 139(4):227-233
13. Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, Moy TF, Becker LC, Faraday N (2006) Sex differences in platelet reactivity and response to low-dose aspirin therapy. Jama 295(12):1420-1427
14. Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, Pettinella C, Recchiuti A, Ferrante E, Ciabattoni G, Davi G, Patrono C (2009) Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: Implications for aspirin "Resistance". J Am Coll Cardiol 53(8):667-677
15. Ortel TL, James AH, Thames EH, Moore KD, Greenberg CS (2000) Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center. Thromb Haemost 84(1):93-97
16. Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W (2000) Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 83(2):316-321
17. Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, Peskar BA (1980) Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 17(3-4):317-327
18. Roberts MS, McLeod LJ, Cossum PA, Vial JH (1984) Inhibition of platelet function by a controlled release acetylsalicylic acid formulation-single and chronic dosing studies. Eur J Clin Pharmacol 27(1):67-74
19. Frelinger AL III, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, Michelson AD (2006) Residual arachidonic acid-induced platelet activation via an adenosine diphosphatedependent but cyclooxygenase-1-and cyclooxygenase-2- independent pathway: A 700-patient study of aspirin resistance. Circulation 113(25):2888-2896
20. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38(8):904-909
21. Landgrebe J, Wurst W, Welzl G (2002) Permutation-validated principal components analysis of microarray data. Genome Biol 3(4):research0019.1- research0019.11
22. Shah SH, Hauser ER, Bain JR, Muehlbauer MJ, Haynes C, Stevens RD, Wenner BR, Dowdy ZE, Granger CB, Ginsburg GS, Newgard CB, Kraus WE (2009) High heritability of metabolomic profiles in families burdened with premature cardiovascular disease. Mol Syst Biol 5:258
23. Yee DL, Bergeron AL, Sun CW, Dong JF, Bray PF (2006) Platelet hyperreactivity generalizes to multiple forms of stimulation. J Thromb Haemost 4(9):2043-2050
24. Williams MS, Weiss EJ, Sabatine MS, Simon DI, Bahou WF, Becker LC, Parise LV, Dauerman HL, French PA, Smyth SS, Becker RC (2010) Genetic regulation of platelet receptor expression and function: Application in clinical practice and drug development. Arterioscl Thromb Vasc Biol 30(12):2372-2384. doi:10.1161/ATVBAHA.110.218131
25. Ohmori T, Yatomi Y, Nonaka T, Kobayashi Y, Madoiwa S, Mimuro J, Ozaki Y, Sakata Y (2006) Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: Involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 4(6):1271-1278. doi:10.1111/j.1538-7836.2006.01958.x
26. Zufferey A, Reny JL, Combescure C, de Moerloose P, Sanchez JC, Fontana P (2011) Platelet reactivity is a stable and global phenomenon in aspirin-treated cardiovascular patients. Thromb Haemost 106(3):466-474. doi:10.1160/TH11-04-0226
27. Mathias R, Kim Y, Sung H, Yanek L, Mantese V, Hererra-Galeano E, Ruczinski I, Wilson A, Faraday N, Becker L, Becker D (2010) A combined genome-wide linkage and association approach to find susceptibility loci for platelet function phenotypes in European American and African American families with coronary artery disease. BMC Med Genomics 3(1):22
28. Johnson AD, Yanek LR, Chen M-H, Faraday N, Larson MG, Tofler G, Lin SJ, Kraja AT, Province MA, Yang Q, Becker DM, O'Donnell CJ, Becker LC (2010) Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat Genet 42(7):608-613. http://www. nature.com/ng/journal/v42/n7/suppinfo/ng.604-S1.html
29. Cuisset T, Frere C, Quilici J, Gaborit B, Bali L, Poyet R, Faille D, Morange PE, Alessi M-C, Bonnet J-L (2009) Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting. Am Heart J 157(5):889-893
30. Patrono C, Rocca B (2007) Drug insight: Aspirin resistance-fact or fashion? Nature clinical practice cardiovascular medicine 4(1):42-50. doi:10.1038/ncpcardio0728
31. Angiolillo DJ, Suryadevara S (2009) Aspirin and clopidogrel: Efficacy and resistance in diabetes mellitus. Best Pract Res Clin Endocrinol Metab 23(3):375-388
32. Hayward CPM, Harrison P, Cattaneo M, Ortel TL, Rao AK, The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2006) Platelet function analyzer (PFA)-100-closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 4(2):312-319